An interventional study of Ren-Nu and KetoCitra in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Richard Fatica. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Richard Fatica · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 50th largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2026, is one of 13 with no phase, reaches primary completion later than 10 of the 24 other live ones, and was the 83rd registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 19–55 · Men only · Healthy volunteers
Kenneth Hallows · Sites in United States
Ages 18–60
Mayo Clinic · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, China, United Kingdom
Ages 18–65
Calico Life Sciences LLC · Sites in United States, Australia, Belgium and 9 more countries
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 18 · Phase 4 2
First in 1998; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 48 across the 63 interventional studies, 90 across the 22 observational. Of the 59 that completed or were terminated, 34 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 85 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Richard Fatica as lead sponsor.
Richard Fatica has 1 study filed under Polycystic Kidney, Autosomal Dominant — fewer than ten, so there is no comparison to draw.
16 of the studies in Polycystic Kidney, Autosomal Dominant with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05193981Mayo ClinicA Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD | 2026-12 |
| NCT05288998Mayo ClinicIntrarenal Microvasculature in ADPKD | 2026-12 |
| NCT06786260Loma Linda UniversityDi-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease | 2026-12 |
| NCT04344769Mayo ClinicCharacterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 2026-12 |
| NCT04630613Mayo ClinicNOX4 and Related Biomarkers in ADPKD | 2026-12 |
Add all 16 to your calendar (.ics) → With an account.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.
The goal of the Ren-Nu program aims to improve the metabolic health of ADPKD patients by implementing a plant-focused, kidney-safe, ketogenic diet supported by medical food KetoCitra®. It is a dietitian-led, online group program focused on ketogenic metabolic therapy with rolling recruitment .
For 12 weeks, participants will be remotely directed through the Ren-Nu program by an experienced renal dietitian where they will learn to implement diet and lifestyle changes by completing weekly web-based classes on nutrition principles and food preparation. A continuous glucose monitor (CGM) will be provided for use during the study. Additionally, they will use a smartphone application to track nutrient intake, self-monitor biomarkers, implement mindfulness practice, and participate in facilitated discussions to build community support. Each participant will meet remotely with the renal dietitian and complete laboratory safety monitoring throughout the program to tailor dietary recommendations for optimal compliance. The study will involve visits to the research institution, histories, physical examinations and laboratory work.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult (18 years or older)
Exclusion Criteria:
Intolerance or allergy to any of the ingredients in the provided medical food
Severe or rare underlying health conditions may cause a safety risk when taking the medical food. Those underlying health conditions will be assessed by the enrolling physician and include but are not limited to:
Current use of any of the following medications or supplements which could affect safety or compliance with this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nutritional counseling and instruction in a ketogenic diet and nutritional food supplement
Dietary Supplement: Ren-Nu and KetoCitra
This is a structured, nutritionist monitored program supplemented with a nutritional food product, while monitoring metabolic parameters
Also known as: Continuous glucose monitoring, intermittent fasting, Nutritional counseling
Change in Serum Renal Function
Change from baseline of renal function assessment as measured by creatinine based estimated glomerular filtration rate.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Serum Hepatic Function Biomarkers
Change from baseline of serum liver panel biomarkers to track safety signals. Biomarkers include: AST (U/L), ALT (U/L), and LDH (U/L). Measured via standard clinical laboratory assays.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Glycemic Control
Change from baseline of glycemic control as measured by aggregate of Hgb A1c and Homeostatic model assessment of insulin resistance (HOMA-IR).
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Systemic Inflammation Markers
Change from baseline of inflammatory biomarkers as an aggregate using: serum C-reactive protein \[(CRP) mg/dL\] and homocysteine (umol/L). Measured via standard clinical laboratory assays.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Serum Measures of Lipids
Change from baseline of of lipids using fasting serum lipid panel to track cholesterol and fat levels. This includes: total cholesterol (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), and triglycerides (mg/dL).
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in 24-Hour Urine Collection to track Lithogenic Risk
Change from baseline of 24-hour urine analytes in aggregate to assess lithogenic risk. The analytes will include calcium (mg/day), creatinine (mg/day), citrate (mg/day), oxalate (mg/day), uric acid (mg/day), sodium (mmol/day), chloride (mmol/day), magnesium (mg/day), ammonium (mmol/day), sulfate (mmol/day), phosphorus (mg/day), urea nitrogen (g/day), and urine pH. Measured via standard clinical laboratory assays.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Glycemic Variability via a Continuous Glucose Monitor (CGM)
Change from baseline in glycemic variability includes mean glucose (mg/dL) measured over a period of time and compared to before and at the end of the Ren-Nu program. This will be measured using the FreeStyle Libre 3 System.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Anthropometric Measures
Change from baseline in body weight (kg) and body mass index (kg/m²), calculated from measured height and weight using standardized clinic procedures.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Blood Pressure
Change from baseline in systolic and diastolic blood pressure. Seated blood pressure (mmHg) is taken throughout the 4 week orientation period and the 12 week nutritional dietary program. This is measured using a calibrated automated blood pressure machine after 5 minutes of rest.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in Serum Fatty Acid
Change from baseline of serum free fatty acid (FFA, mmol/L).
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in health-related quality of life as assessed by the Quality of Life: Short-Form Health Survey 12 (SF-12v2)
Participants will complete the Quality of Life: Short-Form Health Survey 12 (SF-12v2) on Day 0 and Day 120. Scores are standardized by mean. A higher score indicates a better-than-average health-related quality of life, while a lower score suggests a below-average health-related quality of life.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Change in self reported mental and physical health outcomes
This is reported as a change in participant reported mental health status measured via both the Quality of Life: Short-Form Health Survey 12 (SF-12v2) and the study-developed Ren-Nu Outcomes survey. The outcomes survey assesses topics such as final weight (kg), final blood pressure (mmHg), current PKD related symptoms, and changes to medications/supplements.
Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu
Assessment of nutrition knowledge following the structured nutrition education program
Self reported participant nutrition knowledge of the nutritional program at the end of the program. This is a study-developed questionnaire and these questions are multiple choice with a low score reflecting lower nutritional knowledge of the dietary program and a high score reflecting higher nutritional knowledge of the dietary program.
Time frame: Visit 3 (Day 120) after Ren-Nu
Assessment of dietary intervention tolerability following the structured nutrition education program
Self reported participant tolerability of the nutritional program at the end of the program. This is a study-developed questionnaire and questions are multiple choice with a low score reflecting a lower tolerability to the dietary program and a high score reflecting higher satisfaction with the program.
Time frame: Visit 3 (Day 120) after Ren-Nu
Assessment of dietary intervention feasibility following the structured nutrition education program
Self reported participant feasibility of the nutritional program at the end of the program. This is a study-developed questionnaire and questions are multiple choice with a low score reflecting lower feasibility of the dietary program and a high score reflecting higher feasibility of the dietary program.
Time frame: Visit 3 (Day 120) after Ren-Nu
Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.
Of 23 interventional studies with no phase under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 54. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polycystic Kidney, Autosomal Dominant →